Andrew Kuykendall, MD, discusses the rationale behind choosing to evaluate fedratinib in a phase 2 study for patients with atypical chronic myeloid leukemia, chronic neutrophilic leukemia, ...
Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today ...
In an interview, Andrew Kuykendall, MD, discussed fedratinib’s potential as an effective option for patients with ...
The study demonstrated a poor prognosis overall for patients with acute myeloid leukemia (AML) who were previously treated ...
Research from WashU Medicine found a possible new treatment strategy for certain types of blood cancers. The bone marrow of a mouse with a myeloproliferative neoplasm (left) shows fibrosis, or scar ...
The following is a summary of “Outcomes of Patients With Treated Secondary Acute Myeloid Leukemia: A High-Risk Subtype That Warrants an Independent Prognostic Designation,” published in the December ...
While the absolute risk of melanoma by age 40 remained low, survivors of childhood cancer exhibited a standardized incidence ...
A 41-year-old woman with no significant past medical history presents with a solitary nodule on her lower left ankle. The lesion has been growing over the past several months. The patient first ...
A pair of abstracts presented at the 2024 American Society of Hematology (ASH) Annual Meeting & Exhibition suggest that ...
The researchers estimated the 30-year cumulative incidence of any cutaneous malignant neoplasm to be 27.4%. Patients who have undergone blood or marrow transplantation (BMT) are at significant ...
Copyright 2025 The Associated Press. All Rights Reserved. St. Louis County Executive Sam Page speaks during a news conference in Town and Country, Mo., on June 23 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback